Literature DB >> 27261367

Ketamine abuse potential and use disorder.

Yu Liu1, Deyong Lin1, Boliang Wu1, Wenhua Zhou2.   

Abstract

Ketamine is a noncompetitive antagonist of N-methyl-d-asparate (NMDA) receptor and has been long used as an anesthetic agent in humans and veterinary medicine. The present article reviews the epidemiology, pharmacology, neurochemistry, and treatment of ketamine abuse. Ketamine has a unique mood controlling property and a number of studies have demonstrated a significant and rapid antidepressant effect of ketamine. However, the therapeutic value of ketamine to treat psychiatric disorders faces a major challenge that ketamine also owns significant reinforcing and toxic effects. Its abuse has posted severe harms on individuals and society. Disrupted learning and memory processing has long been related with ketamine use. It is hypothesized that ketamine blocks NMDA receptors on gamma-aminobutyric acid (GABA) neurons inside the thalamic reticular nucleus, which leads to disinhibition of dopaminergic neurons and increased release of dopamine. Currently, there is no specific treatment for treating every ketamine patient presenting peripheral toxicity. Interestingly, ketamine psychotherapy has been suggested to be a promising approach to treat addiction of other drugs. Future research can continue to develop creative ways to investigate potential mechanism and treatments related to ketamine abuse that have posted severe individual and social harms.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-depressant; Ketamine abuse; Neurobiology; Pharmacology; Toxic effect

Mesh:

Substances:

Year:  2016        PMID: 27261367     DOI: 10.1016/j.brainresbull.2016.05.016

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  31 in total

Review 1.  Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.

Authors:  Jonathan DePierro; Lauren Lepow; Adriana Feder; Rachel Yehuda
Journal:  Biol Psychiatry       Date:  2019-07-24       Impact factor: 13.382

Review 2.  Do specific NMDA receptor subunits act as gateways for addictive behaviors?

Authors:  F W Hopf
Journal:  Genes Brain Behav       Date:  2016-11-18       Impact factor: 3.449

3.  Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval.

Authors:  Keith A Trujillo; Colleen Y Heller
Journal:  Behav Brain Res       Date:  2019-10-05       Impact factor: 3.332

Review 4.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

5.  The Effect of the Low Glutamate Diet on the Reduction of Psychiatric Symptoms in Veterans With Gulf War Illness: A Pilot Randomized-Controlled Trial.

Authors:  Elizabeth T Brandley; Anna E Kirkland; Michael Baron; James N Baraniuk; Kathleen F Holton
Journal:  Front Psychiatry       Date:  2022-06-20       Impact factor: 5.435

6.  Ketamine-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion and Hyponatremia.

Authors:  Kelash Kumar; Fnu Poonam; Teesha Rani; Fnu Prinka; Cece E Ibeson; Ifeanyi Nwosu; Vijay Shetty; Anthony N Kalloo
Journal:  Cureus       Date:  2022-06-14

7.  Depression in chronic ketamine users: Sex differences and neural bases.

Authors:  Chiang-Shan R Li; Sheng Zhang; Chia-Chun Hung; Chun-Ming Chen; Jeng-Ren Duann; Ching-Po Lin; Tony Szu-Hsien Lee
Journal:  Psychiatry Res Neuroimaging       Date:  2017-09-05       Impact factor: 2.376

8.  4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels.

Authors:  Arvie Abiero; Chrislean Jun Botanas; Raly James Custodio; Leandro Val Sayson; Mikyung Kim; Hyun Jun Lee; Hee Jin Kim; Kun Won Lee; Youngdo Jeong; Joung-Wook Seo; In Soo Ryu; Yong Sup Lee; Jae Hoon Cheong
Journal:  Psychopharmacology (Berl)       Date:  2019-12-11       Impact factor: 4.530

9.  mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine.

Authors:  Runfang Xie; Jiming Xie; Yi Ye; Xueyan Wang; Fan Chen; Lin Yang; Youyi Yan; Linchuan Liao
Journal:  J Mol Neurosci       Date:  2020-01-02       Impact factor: 3.444

10.  Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice.

Authors:  Priyodarshan Goswamee; Remington Rice; Elizabeth Leggett; Fan Zhang; Sofia Manicka; Joseph H Porter; A Rory McQuiston
Journal:  Neuropharmacology       Date:  2022-01-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.